StockData

Orchestra BioMed Holdings, Inc. (OBIO) stock

OBIONasdaqSurgical & Medical Instruments & ApparatusFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 10, 2026Score 9/30
$7.25+1.10 (+17.89%)

Close on Nov 13, 2026Market cap $435.76MP/E –Yield –

Orchestra BioMed gross margin

Gross margin is gross profit as a percentage of revenue.

Orchestra BioMed's gross margin for the twelve months ending Sep 30, 2026 was 99.6%. For fiscal 2025 it was 99.4%, against 92.3% the year before.

Annual gross margin

PeriodPeriod endValueChange (pts)
FY2025Dec 31, 202599.4%+7.2
FY2024Dec 31, 202492.3%−1.0
FY2023Dec 31, 202393.3%−0.8
FY2022Dec 31, 202294.0%–

Quarterly gross margin

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange (pts)
Q3 FY2026Sep 30, 202669.2%−25.1
Q2 FY2026Jun 30, 202671.6%−22.9
Q1 FY2026Mar 31, 202670.9%−24.0
Q4 FY2025Dec 31, 202599.8%+22.8
Q3 FY2025Sep 30, 202594.3%+1.2
Q2 FY2025Jun 30, 202594.5%+0.2
Q1 FY2025Mar 31, 202594.9%+0.4
Q4 FY2024Dec 31, 202477.1%−5.0
Q3 FY2024Sep 30, 202493.1%+2.9
Q2 FY2024Jun 30, 202494.3%+0.2
Q1 FY2024Mar 31, 202494.5%−1.7
Q4 FY2023Dec 31, 202382.1%−13.1
Q3 FY2023Sep 30, 202390.2%−5.0
Q2 FY2023Jun 30, 202394.1%+9.1
Q1 FY2023Mar 31, 202396.2%+1.1
Q4 FY2022Dec 31, 202295.2%–
Q3 FY2022Sep 30, 202295.2%–
Q2 FY2022Jun 30, 202285.0%–
Q1 FY2022Mar 31, 202295.2%–

More Orchestra BioMed figures

See a number that looks wrong?